ダラツムマブ
多発性骨髄腫
Haematologica 106 (2): 589–592. doi:10.3324/haematol.2019.242974. PMC 7849566. PMID 32193250. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849566/.
1 2 “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12): 1522. (2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑ “Daratumumab in multiple myeloma”. Cancer 125 (14): 2364–2382. (2019). doi:10.1002/cncr.32065. PMID 30951198.
↑ “Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma”. Journal of Clinical Medicine 9 (4): 1195. (2020). doi:10.3390/jcm9041195. PMC 7230744. PMID 32331242.